Susquehanna International Group
XFOR icon

Susquehanna International Group’s X4 Pharmaceuticals XFOR Stock Holding History

Susquehanna International Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-947
Closed -$19K – 13378
2024
Q3 		$19K Sell
947
-606
-39% -$12.6K ﹤0.01% 11634
2024
Q2 		$27K Sell
1,553
-5,244
-77% -$172K ﹤0.01% 11590
2024
Q1 		$283K Buy
6,797
+4,204
+162% +$117K ﹤0.01% 9825
2023
Q4 		$65.4K Buy
2,593
+1,993
+332% +$48.5K ﹤0.01% 11592
2023
Q3 		$19.6K Sell
600
-5,653
-90% -$247K ﹤0.01% 11604
2023
Q2 		$364K Buy
6,253
+4,960
+384% +$255K ﹤0.01% 9047
2023
Q1 		$33.8K Sell
1,293
-124
-9% -$3.64K ﹤0.01% 11866
2022
Q4 		$42.1K Buy
1,417
+1,004
+243% +$47.6K ﹤0.01% 11479
2022
Q3 		$21K Buy
+413
New +$14.3K ﹤0.01% 12592
2022
Q2 		– Sell
-1,013
Closed -$53K – 14081
2022
Q1 		$53K Sell
1,013
-1,744
-63% -$100K ﹤0.01% 12292
2021
Q4 		$189K Buy
+2,757
New +$349K ﹤0.01% 11512

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Susquehanna International Group's XFOR Position: Q1 2026 in Review

Susquehanna International Group increased its X4 Pharmaceuticals (XFOR) stake by 3,768% in Q1 2026, buying an estimated $3.12M and bringing the position to 856,222 shares worth $3.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4922.

Susquehanna International Group first reported a position in XFOR in Q2 2019 and has held it in 19 quarters since. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Susquehanna International Group held 856,222 shares of X4 Pharmaceuticals worth $3.54M as of Q1 2026.
  • Susquehanna International Group bought 834,087 X4 Pharmaceuticals shares in Q1 2026, an estimated $3.12M.
  • X4 Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4922 holding.
  • Susquehanna International Group first reported a position in X4 Pharmaceuticals in Q2 2019 and has held it in 19 quarters since.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.